The aggressive triple-negative phenotype of breast cancer (negative for estrogen and progesterone receptors and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 [ERBB2] [formerly human epidermal growth factor receptor 2 (HER2)]) is considered by some investigators to be a relative contraindication to breast-conserving therapy.
B reast cancers are characterized by a wide spectrum of clinical, pathologic, and molecular features. Various well-established tumor markers have been used to determine prognosis and response to therapy, including molecular biomarkers allowing for the identification of distinct subtypes of breast cancer. The most common and useful classification is based on the expression of estrogen receptors (ERs), progesterone receptors (PRs), and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) (formerly human epidermal growth factor receptor 2 [HER2]). [1] [2] [3] [4] Triple-negative breast cancers (TNBCs) are those that lack or only minimally express ERs, PRs, and ERBB2. Triplenegative breast cancers account for approximately 10% to 20% of newly diagnosed breast cancers and tend to exhibit a more aggressive clinical behavior, a metastatic pattern, and poor prognosis compared with other subtypes. 5, 6 Although targeted therapies have been developed for tumors that express ERs, PRs, or ERBB2, treatment for tumors that lack these markers remains challenging. The lack of targeted therapy and the aggressive nature of TNBCs have resulted in controversy as to whether breastconserving therapy (BCT) is appropriate treatment for these tumors. Several large randomized clinical trials demonstrate equivalent overall survival (OS) for patients undergoing mastectomy compared with those undergoing BCT; however, none included an analysis of molecular subtypes or TNBC. 7, 8 For patients with TNBC who undergo BCT, many investigators suggest that local recurrence (LR), regional recurrence (RR), and distant metastasis are increased and that OS is decreased compared with the outcomes of patients with non-TNBC subtypes.
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Given the aggressive nature of TNBC, one can reasonably question whether BCT is appropriate. The purpose of this study was to compare outcomes between patients with TNBC and non-TNBC who underwent BCT to determine whether LR is increased in TNBC patients.
Methods
This study was performed with the approval of the institutional review board of Cedars-Sinai Medical Center. Informed consent was waived for this retrospective review of a prospective database. We reviewed a prospectively maintained database of patients undergoing evaluation and treatment for breast cancer from January 1, 2000, through May 30, 2012. Women ages 18 through 85 years with newly diagnosed stages I through III breast cancer were identified. Approximately 20 surgeons performed the procedures that qualified for inclusion in this study. The surgeons did not follow a standardized surgical management protocol. Men, patients undergoing neoadjuvant chemotherapy or mastectomy, and patients with fewer than 90 days of follow-up were excluded from the study. In addition, patients with positive margins were excluded. Most surgeons considered margins to be negative if the tumor-free margin was larger than 1 mm; some surgeons were content if no tumor cells were found at the ink of the surgical specimen on pathologic review. Of the remaining patients, we included only those for whom ER, PR, and ERBB2 status were available. We identified a total study sample of 1851 patients.
Patients were then categorized according to tumor phenotypic subtype using the presence or absence of tumor markers. Specifically, tumors were classified into luminal A (positive for ER or PR and negative for ERBB2), luminal B (positive for ER or PR and ERBB2), ERBB2 (negative for ER and PR and positive for ERBB2), and TNBC (negative for all 3 markers) subtypes based on immunohistochemical identification of these markers on biopsied or excised specimens. A positive ERBB2 marker was defined as immunohistochemical identification (ERBB2 receptor protein on the surface of cells in the breast cancer tissue sample) of 3+ and/or amplified (ratio, >2.0) expression of ERBB2 on fluorescence in situ hybridization. Patient and tumor characteristics examined included age at diagnosis, tumor size, histologic subtype, grade, stage, lymph node status, adjuvant systemic treatment, and adjuvant radiotherapy. As is standard practice, conventional whole-breast radiotherapy with opposing tangents was used in nearly all patients. Most patients with invasive cancer at our institution receive a boost dose of radiotherapy to the primary site. The primary outcome measure was LR. Secondary outcome measures included RR, distant recurrence (DR), and OS. As is standard practice, most of the patients were followed up with biannual mammography for 2 years and then annual mammography and physical examination thereafter. Time to recurrence was calculated from the date of diagnosis to the date of recurrence. Survival was calculated from the date of diagnosis to the date of death or the most recent follow-up for surviving patients.
Differences on normally distributed variables across the 4 cancer subtypes were assessed by analysis of variance and Tukey post hoc tests. Differences on nonnormally distributed numerical variables across the 4 subtypes were assessed by the Kruskal-Wallis test and Wilcoxon rank sum post hoc tests. Differences between TNBC and non-TNBC on normally distributed variables were assessed by the independentsamples t test. Differences between TNBC and non-TNBC on nonnormally distributed numerical variables were assessed by the Wilcoxon rank sum test. Differences on dichotomous variables were assessed by the χ 2 test or the Fisher exact test, as appropriate. Overall survival and freedom from recurrence were estimated by the Kaplan-Meier method and compared across groups by the log-rank test. Hazard ratios (HRs) and their 95% confidence intervals were estimated using Cox proportional hazards regression models. Multivariable Cox models were used to estimate the association of TNBC with the risk of death and recurrence, adjusting for potentially confounding variables. Time to recurrence for the Cox models was truncated at 5 years. Candidate predictors in the Cox models for recurrence were age (<50, 50 to <80, and ≥80 years), tumor size (<2, 2 3] cm; P < .001). In addition, TNBCs were more frequently high grade (P < .001), were stage II or III vs stage I (P < .001), and had predominantly infiltrating ductal histologic type tumors (P < .001). Overall, 26.2% of patients had node-positive disease. Of the subtypes, ERBB2 had the strongest association with nodal positivity (35.0%) compared with TNBC (30.5%) or the luminal A (24.3%) or luminal B (30.4%) subtypes (P = .04). When comparing TNBC with non-TNBC patients, lymph node positivity was not significantly different (30.5% vs 25.5%; P = .10).
Patients were treated with adjuvant systemic therapy and/or radiotherapy. Overall, 49.3% of patients received chemotherapy, whereas 91.2% received radiotherapy. Patients with TNBC (85.5%) and the ERBB2 subtype (85.0%) were more likely to receive chemotherapy compared with patients with the lu- Copyright 2014 American Medical Association. All rights reserved.
minal B (65.3%) and especially the luminal A (38.2%) subtypes (P < .001). A total of 143 (8.8%) patients did not receive radiotherapy. Of these, 12 patients had TNBC and 106 had luminal A, 20 had luminal B, and 5 had ERBB2 tumor subtypes. Within the TNBC group, 8 patients had comorbid conditions that precluded them from receiving radiotherapy, and 4 patients refused radiotherapy although it was recommended. Within the luminal A and B groups, patients had smaller tumors and were generally older with comorbid conditions and therefore did not receive radiotherapy. Within the ERBB2 group, 2 patients refused the treatment; 3 had significant comorbidities, and although radiotherapy was recommended, they declined. Most of the patients in all groups received adjuvant whole-breast radiotherapy or accelerated partialbreast radiotherapy (94.1% vs 3.8%). Forty-six LRs were observed among the entire study population, including 11 (4.7%) in the TNBC group, 8 (12.5%) in the ERBB2 group, 23 (1.7%) in the luminal A group, and 4 (1.9%) in the luminal B group. Kaplan-Meier-estimated freedom from LR at 5 years was 93% for the TNBC, 96% for ERBB2, 95% for luminal A, and 96% for luminal B (P = .13) groups. Figure 1 Table 2) .
We observed a total of 21 RRs, including 3 (1.3%) in the TNBC, 4 (6.3%) in the ERBB2, 9 (0.7%) in the luminal A, and 5 (2.4%) in the luminal B groups. Kaplan-Meier-estimated freedom from RR at 5 years was 98% for the TNBC, 84% for the ERBB2, 98% for the luminal A, and 96% for the luminal B groups (P < .001) (Figure 2 Distant recurrences were the most frequent recurrences seen among all patients, with a total of 66 patients presenting with metastatic disease after BCT. Of these, 21 (9.0%) were in the TNBC group, 5 (7.8%) in the ERBB2 group, 31 (2.3%) in the luminal A group, and 9 (4.2%) in the luminal B Table 5) . Kaplan-Meier analysis of OS is shown in Figure 4 .
Discussion
Breast cancer subtypes are known to have phenotypic diversity with regard to tumor aggressiveness and response to therapy. 3 Triple-negative breast cancer specifically is challenging to treat because it lacks a targeted treatment approach, is associated with a poor prognosis, and, in some studies, has an increased risk of LR. [13] [14] [15] This study validates that TNBC patients are younger, present with tumors of a higher grade and larger size, and present at a more advanced stage compared with non-TNBC patients. The study also validates that OS is worse among this group of patients. These findings are consistent with the current literature, which indicates that the triple-negative subtype is generally more aggressive, with worse prognosis overall. 5, 16, 17 Although breast cancer patients undergoing BCT have longterm outcomes equivalent to those of patients treated with mastectomy, significant debate remains regarding BCT as an appropriate treatment of TNBC. 
